Analyst Price Targets — IMRX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 8, 2026 10:51 am | Li Watsek | Cantor Fitzgerald | $17.00 | $5.10 | TheFly | Immuneering initiated with an Overweight at Cantor Fitzgerald |
| March 9, 2026 10:50 am | — | Piper Sandler | $12.00 | $5.62 | TheFly | Immuneering price target lowered to $12 from $13 at Piper Sandler |
| October 29, 2025 12:51 pm | — | Mizuho Securities | $12.00 | $6.49 | TheFly | Immuneering price target raised to $12 from $10 at Mizuho |
| September 25, 2025 12:57 pm | Jay Olson | Oppenheimer | $30.00 | $9.23 | TheFly | Immuneering price target raised to $30 from $21 at Oppenheimer |
| April 2, 2024 6:36 am | Graig Suvannavejh | Mizuho Securities | $8.00 | $2.75 | StreetInsider | Immuneering Corporation (IMRX) PT Lowered to $8 at Mizuho, 'maintain our favorable view on IMRX's innovative approach' |
| March 15, 2024 6:26 am | Michael Yee | Jefferies | $3.00 | $1.91 | StreetInsider | Jefferies Downgrades Immuneering Corporation (IMRX) to Hold |
| September 30, 2022 12:16 pm | Swapnil Malekar | Piper Sandler | $41.00 | $15.50 | TheFly | Immuneering transitions to clinical stage with IND approval, says Piper Sandler |
| July 9, 2022 6:13 am | Geulah Livshits | Loop Capital Markets | $18.00 | $7.28 | Pulse 2.0 | Immuneering (IMRX) Stock: Why It Surged 28.85% |
Latest News for IMRX
NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, previously announced on June 15, 2026, that Andrew Gengos was named Chief Financial Officer of the Company, effective as of July 16, 2026 (the "Start Date").
NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, previously announced on June 15, 2026, that Andrew Gengos was named Chief Financial Officer of the Company, effective as of July 16, 2026 (the “Start Date”). In connection with the commencement of Mr.
Immuneering (IMRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- Former CFO of Terns Pharmaceuticals to join Immuneering - - Seasoned public company CFO strengthens team with over 25 years of leadership in biotech – NEW YORK, June 15, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced the appointment of Andrew Gengos as Chief Financial Officer,…
Immuneering stock rises after dosing the first patient in a pivotal phase III study of atebimetinib plus mGnP for first-line metastatic pancreatic cancer.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for IMRX.
U.S. House Trading
No House trades found for IMRX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.